

U.S. Food and Drug Administration
Protecting and Promoting *Your* Health

Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Olmesartan (marketed as Benicar) Information

Benicar (olmesartan) is in the class of drugs called angiotensin II receptor blockers (ARBs). It is approved for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Related Information

- **FDA Drug Safety Communication: FDA review of cardiovascular risks for diabetics taking hypertension drug olmesartan not conclusive: label updates required (/Drugs/DrugSafety/ucm402323.htm)**
6/24/2014
- **FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil (/Drugs/DrugSafety/ucm359477.htm)**
7/3/2013
- **FDA Drug Safety Communication: Safety Review Update of Benicar (olmesartan) and cardiovascular events (/Drugs/DrugSafety/ucm251268.htm)** [ARCHIVED]
4/14/2011
- **FDA Drug Safety Communication: Ongoing safety review of the angiotensin receptor blockers and cancer (/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm218845.htm)** [ARCHIVED]
7/15/2010
- **FDA Drug Safety Communication: Ongoing safety review of Benicar(olmesartan) and cardiovascular events (/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm215222.htm)** [ARCHIVED]
6/11/2010
- **FDA Drug Safety Podcast for Healthcare Professionals: Ongoing safety review of Benicar and cardiovascular events (/Drugs/DrugSafety/DrugSafetyPodcasts/ucm217335.htm)** [ARCHIVED]
6/2011
- **Benicar (olmesartan): Ongoing Safety Review (/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm215249.htm)**
MedWatch (6/11/2010) Updated (4/14/2011)
- **Angiotensin Receptor Blockers (ARBs) Information (/Drugs/DrugSafety/InformationbyDrugClass/ucm218897.htm)**

Labeling and Regulatory History from Drugs@FDA

- **Olmesartan (marketed as Benicar) Prescribing and Labeling Information**
(<http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=benicar&SearchType=BasicSearch>)

Contact FDA

1-800-332-1088
1-800-FDA-0178 Fax

Report a Serious Problem

MedWatch Online (<https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm>)

Regular Mail: Use postage-paid **FDA Form 3500**
(<http://www.fda.gov/downloads/Safety/MedWatch/DownloadForms/UCM082725.pdf>)

Mail to: MedWatch 5600 Fishers Lane
Rockville, MD 20857

More in Postmarket Drug Safety Information for Patients and Providers
(</Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/default.htm>)

Index to Drug-Specific Information
(</Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111085.htm>)